Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans
Prepulse inhibition of acoustic startle refers to the reduction in the startle response when the startling stimulus is preceded by a weak prepulse stimulus. This phenomenon provides an operational measure of sensorimotor gating that has been found to be reduced in patients with schizophrenia and rat...
Saved in:
Published in | Psychopharmacologia Vol. 143; no. 4; pp. 365 - 372 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Berlin
Springer
01.04.1999
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
ISSN | 0033-3158 1432-2072 |
DOI | 10.1007/s002130050960 |
Cover
Abstract | Prepulse inhibition of acoustic startle refers to the reduction in the startle response when the startling stimulus is preceded by a weak prepulse stimulus. This phenomenon provides an operational measure of sensorimotor gating that has been found to be reduced in patients with schizophrenia and rats treated with serotonin agonists or serotonin releasers.
In this study, we compared the effects of a serotonin releaser, MDMA, on prepulse inhibition in laboratory rats and healthy human volunteers. In particular, we investigated whether MDMA disrupts PPI in humans as observed in animal studies.
Rats were tested after placebo and MDMA in a counterbalanced order at an interval of 1 week, with separate groups of rats being used for each dose of MDMA (1.7, 5.4 and 17.0 mg/kg). On each test day, rats were first tested after no injections and retested 2 h later, 10 min after a subcutaneous injection of placebo or MDMA. For the human study, a placebo-controlled within-subject design and double-blind procedures were used. Subjects were examined twice at a 2 to 4 week interval after either placebo or drug administration (order being counterbalanced). On each test day, subjects underwent baseline testing including psychological and PPI measures. Ninety minutes later, subjects received placebo or MDMA (1.7 mg/kg PO) and were retested after 75 min during the peak of behavioral effects of MDMA.
As expected, MDMA decreased prepulse inhibition in a dose-related fashion in rats. In contrast, a typical recreational dose of MDMA (1.7 mg/kg, orally) increased prepulse inhibition in subjects experiencing robust psychological effects.
This surprising disparity between the effects of the drug in rats and humans may reflect a species-specific difference in the mechanism of action of MDMA or in the behavioral expression of a similar pharmacological effect, or both. |
---|---|
AbstractList | Rationale: Prepulse inhibition of acoustic startle refers to the reduction in the startle response when the startling stimulus is preceded by a weak prepulse stimulus. This phenomenon provides an operational measure of sensorimotor gating that has been found to be reduced in patients with schizophrenia and rats treated with serotonin agonists or serotonin releasers. Objective: In this study, we compared the effects of a serotonin releaser, MDMA, on prepulse inhibition in laboratory rats and healthy human volunteers. In particular, we investigated whether MDMA disrupts PPI in humans as observed in animal studies. Methods: Rats were tested after placebo and MDMA in a counterbalanced order at an interval of 1 week, with separate groups of rats being used for each dose of MDMA (1.7, 5.4 and 17.0 mg/kg). On each test day, rats were first tested after no injections and retested 2 h later, 10 min after a subcutaneous injection of placebo or MDMA. For the human study, a placebo-controlled within-subject design and double-blind procedures were used. Subjects were examined twice at a 2 to 4 week interval after either placebo or drug administration (order being counterbalanced). On each test day, subjects underwent baseline testing including psychological and PPI measures. Ninety minutes later, subjects received placebo or MDMA (1.7 mg/kg PO) and were retested after 75 min during the peak of behavioral effects of MDMA. Results: As expected, MDMA decreased prepulse inhibition in a dose-related fashion in rats. In contrast, a typical recreational dose of MDMA (1.7 mg/kg, orally) increased prepulse inhibition in subjects experiencing robust psychological effects. Conclusions: This surprising disparity between the effects of the drug in rats and humans may reflect a species-specific difference in the mechanism of action of MDMA or in the behavioral expression of a similar pharmacological effect, or both. Prepulse inhibition of acoustic startle refers to the reduction in the startle response when the startling stimulus is preceded by a weak prepulse stimulus. This phenomenon provides an operational measure of sensorimotor gating that has been found to be reduced in patients with schizophrenia and rats treated with serotonin agonists or serotonin releasers. In this study, we compared the effects of a serotonin releaser, MDMA, on prepulse inhibition in laboratory rats and healthy human volunteers. In particular, we investigated whether MDMA disrupts PPI in humans as observed in animal studies. Rats were tested after placebo and MDMA in a counterbalanced order at an interval of 1 week, with separate groups of rats being used for each dose of MDMA (1.7, 5.4 and 17.0 mg/kg). On each test day, rats were first tested after no injections and retested 2 h later, 10 min after a subcutaneous injection of placebo or MDMA. For the human study, a placebo-controlled within-subject design and double-blind procedures were used. Subjects were examined twice at a 2 to 4 week interval after either placebo or drug administration (order being counterbalanced). On each test day, subjects underwent baseline testing including psychological and PPI measures. Ninety minutes later, subjects received placebo or MDMA (1.7 mg/kg PO) and were retested after 75 min during the peak of behavioral effects of MDMA. As expected, MDMA decreased prepulse inhibition in a dose-related fashion in rats. In contrast, a typical recreational dose of MDMA (1.7 mg/kg, orally) increased prepulse inhibition in subjects experiencing robust psychological effects. This surprising disparity between the effects of the drug in rats and humans may reflect a species-specific difference in the mechanism of action of MDMA or in the behavioral expression of a similar pharmacological effect, or both. Prepulse inhibition of acoustic startle refers to the reduction in the startle response when the startling stimulus is preceded by a weak prepulse stimulus. This phenomenon provides an operational measure of sensorimotor gating that has been found to be reduced in patients with schizophrenia and rats treated with serotonin agonists or serotonin releasers.RATIONALEPrepulse inhibition of acoustic startle refers to the reduction in the startle response when the startling stimulus is preceded by a weak prepulse stimulus. This phenomenon provides an operational measure of sensorimotor gating that has been found to be reduced in patients with schizophrenia and rats treated with serotonin agonists or serotonin releasers.In this study, we compared the effects of a serotonin releaser, MDMA, on prepulse inhibition in laboratory rats and healthy human volunteers. In particular, we investigated whether MDMA disrupts PPI in humans as observed in animal studies.OBJECTIVEIn this study, we compared the effects of a serotonin releaser, MDMA, on prepulse inhibition in laboratory rats and healthy human volunteers. In particular, we investigated whether MDMA disrupts PPI in humans as observed in animal studies.Rats were tested after placebo and MDMA in a counterbalanced order at an interval of 1 week, with separate groups of rats being used for each dose of MDMA (1.7, 5.4 and 17.0 mg/kg). On each test day, rats were first tested after no injections and retested 2 h later, 10 min after a subcutaneous injection of placebo or MDMA. For the human study, a placebo-controlled within-subject design and double-blind procedures were used. Subjects were examined twice at a 2 to 4 week interval after either placebo or drug administration (order being counterbalanced). On each test day, subjects underwent baseline testing including psychological and PPI measures. Ninety minutes later, subjects received placebo or MDMA (1.7 mg/kg PO) and were retested after 75 min during the peak of behavioral effects of MDMA.METHODSRats were tested after placebo and MDMA in a counterbalanced order at an interval of 1 week, with separate groups of rats being used for each dose of MDMA (1.7, 5.4 and 17.0 mg/kg). On each test day, rats were first tested after no injections and retested 2 h later, 10 min after a subcutaneous injection of placebo or MDMA. For the human study, a placebo-controlled within-subject design and double-blind procedures were used. Subjects were examined twice at a 2 to 4 week interval after either placebo or drug administration (order being counterbalanced). On each test day, subjects underwent baseline testing including psychological and PPI measures. Ninety minutes later, subjects received placebo or MDMA (1.7 mg/kg PO) and were retested after 75 min during the peak of behavioral effects of MDMA.As expected, MDMA decreased prepulse inhibition in a dose-related fashion in rats. In contrast, a typical recreational dose of MDMA (1.7 mg/kg, orally) increased prepulse inhibition in subjects experiencing robust psychological effects.RESULTSAs expected, MDMA decreased prepulse inhibition in a dose-related fashion in rats. In contrast, a typical recreational dose of MDMA (1.7 mg/kg, orally) increased prepulse inhibition in subjects experiencing robust psychological effects.This surprising disparity between the effects of the drug in rats and humans may reflect a species-specific difference in the mechanism of action of MDMA or in the behavioral expression of a similar pharmacological effect, or both.CONCLUSIONSThis surprising disparity between the effects of the drug in rats and humans may reflect a species-specific difference in the mechanism of action of MDMA or in the behavioral expression of a similar pharmacological effect, or both. |
Author | Hell, D. Remensberger, S. Geyer, M. A. Vollenweider, F. X. |
Author_xml | – sequence: 1 givenname: F. X. surname: Vollenweider fullname: Vollenweider, F. X. – sequence: 2 givenname: S. surname: Remensberger fullname: Remensberger, S. – sequence: 3 givenname: D. surname: Hell fullname: Hell, D. – sequence: 4 givenname: M. A. surname: Geyer fullname: Geyer, M. A. |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1770450$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/10367553$$D View this record in MEDLINE/PubMed |
BookMark | eNp10VFrFDEQB_AgFXutPvoqAYtUcHWys0l2H0u1KrT0RZ-XXHa2l7KbXJOseN_elJ6oBQMhBH75M5k5Ygc-eGLspYD3AkB_SAC1QAAJnYInbCUarKsadH3AVgCIFQrZHrKjlG6hrKZtnrFDAai0lLhid9fbbUguE6dxJJsTDyPHd001U97sJvI0uPBzd38z83ZD2czOEz-9-nh19pYHzxP5FKKbQw6R35js_A13nkdTon5QTEviGzJTCeObZTY-PWdPRzMlerE_j9n3i0_fzr9Ul9efv56fXVYWG5UrJa2yoOpWkmq0RLkesJW2xUZrJKEloQSzHrpuUGTEKDsa10KQGiwilX3M3jzkbmO4WyjlfnbJ0jQZT2FJveraGhqlC3z9CN6GJfpSW49C6BZRoSjq1V4t65mGflv-bOKu_93KAk72wCRrpjEab13647SGRkJh1QOzMaQUafwrqb-faP_PRIvHR966XNocfI7GTf959QtVNqHw |
CODEN | PSYPAG |
CitedBy_id | crossref_primary_10_1080_16066350290001704 crossref_primary_10_1177_026988110201600101 crossref_primary_10_1080_02791072_2002_10399952 crossref_primary_10_1080_02791072_2002_10399951 crossref_primary_10_1177_0269881118822156 crossref_primary_10_1016_j_euroneuro_2012_09_005 crossref_primary_10_1038_sj_npp_1300396 crossref_primary_10_1093_schbul_sbn156 crossref_primary_10_1177_0269881105053287 crossref_primary_10_1038_sj_npp_1301324 crossref_primary_10_1371_journal_pone_0258849 crossref_primary_10_1007_s00213_005_0056_x crossref_primary_10_1016_S0028_3908_03_00073_X crossref_primary_10_1016_j_biopsych_2010_08_003 crossref_primary_10_1016_j_euroneuro_2015_12_025 crossref_primary_10_1007_s00213_007_0843_7 crossref_primary_10_1176_appi_ajp_158_10_1687 crossref_primary_10_3389_fpsyt_2017_00232 crossref_primary_10_1016_j_neuro_2024_06_014 crossref_primary_10_1017_S1461145707008322 crossref_primary_10_1038_sj_npp_1301350 crossref_primary_10_3389_fpsyt_2018_00144 crossref_primary_10_1007_s00213_009_1545_0 crossref_primary_10_1080_02791072_2001_10400568 crossref_primary_10_1038_sj_npp_1301556 crossref_primary_10_1177_155005940703800207 crossref_primary_10_31887_DCNS_2001_3_4_fxvollenweider crossref_primary_10_1024_1016_264X_19_3_139 crossref_primary_10_1177_0269881104042615 crossref_primary_10_1177_0269881107077734 crossref_primary_10_1007_s00213_009_1635_z crossref_primary_10_1523_JNEUROSCI_2502_11_2011 crossref_primary_10_1371_journal_pone_0078386 crossref_primary_10_1111_bph_12628 crossref_primary_10_1177_0269881106063271 crossref_primary_10_1038_sj_mp_4001159 crossref_primary_10_1097_00008877_200503000_00009 crossref_primary_10_1177_0269881116650408 crossref_primary_10_1016_j_pharmthera_2009_02_004 crossref_primary_10_1016_j_bbr_2004_04_014 crossref_primary_10_1177_026988110001400308 crossref_primary_10_1146_annurev_clinpsy_121208_131220 crossref_primary_10_1016_j_biopsych_2004_02_030 crossref_primary_10_1007_s00213_008_1072_4 crossref_primary_10_1097_00008877_200006000_00002 crossref_primary_10_1017_S1461145711000101 crossref_primary_10_1007_s00406_007_0753_z crossref_primary_10_1177_0269881108094650 crossref_primary_10_1016_j_pbb_2010_12_011 crossref_primary_10_1017_S1461145709000480 crossref_primary_10_1124_pr_55_3_3 crossref_primary_10_1016_j_heares_2015_11_014 crossref_primary_10_1038_sj_npp_1300086 crossref_primary_10_1016_j_neubiorev_2006_09_009 crossref_primary_10_1016_j_pnpbp_2023_110843 crossref_primary_10_1007_s00213_007_0762_7 crossref_primary_10_1016_j_schres_2018_03_037 crossref_primary_10_1097_00008877_200102000_00005 crossref_primary_10_1038_sj_npp_1301009 crossref_primary_10_1016_S0149_7634_03_00031_9 crossref_primary_10_1016_S0163_7258_03_00003_2 crossref_primary_10_1038_npp_2011_228 crossref_primary_10_1016_S0278_5846_03_00081_2 crossref_primary_10_1016_j_neuropharm_2006_11_006 |
ContentType | Journal Article |
Copyright | 1999 INIST-CNRS Springer-Verlag Berlin Heidelberg 1999. |
Copyright_xml | – notice: 1999 INIST-CNRS – notice: Springer-Verlag Berlin Heidelberg 1999. |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7QG 7QR 7RV 7TK 7X7 7XB 88E 88G 8AO 8FD 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ K9. KB0 M0S M1P M2M NAPCQ P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 |
DOI | 10.1007/s002130050960 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Animal Behavior Abstracts Chemoreception Abstracts Nursing & Allied Health Database Neurosciences Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Pharma Collection Technology Research Database ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Psychology Database Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology ProQuest Central Student Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection Chemoreception Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition Animal Behavior Abstracts ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | ProQuest One Psychology MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1432-2072 |
EndPage | 372 |
ExternalDocumentID | 10367553 1770450 10_1007_s002130050960 |
Genre | Controlled Clinical Trial Research Support, U.S. Gov't, P.H.S Comparative Study Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: NIMH NIH HHS grantid: MH01228 – fundername: NIDA NIH HHS grantid: DA02925 |
GroupedDBID | 40D 40E 95. 95~ AAYXX ABMNI AGWIL ALMA_UNASSIGNED_HOLDINGS CITATION RHV SBY SOJ ~EX .55 3SX IQODW KOW N2Q R9- X7M -4W -BR CGR CUY CVF ECM EIF NPM 3V. 7QG 7QR 7RV 7TK 7X7 7XB 88E 8AO 8FD 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FR3 FYUFA GNUQQ K9. M1P M2M NAPCQ P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 |
ID | FETCH-LOGICAL-c346t-65c6c06285e647535bd385c834773e175e350abd99d6ea1f59efb11e6dc33ec33 |
IEDL.DBID | 7X7 |
ISSN | 0033-3158 |
IngestDate | Fri Jul 11 09:59:57 EDT 2025 Sat Aug 16 19:52:16 EDT 2025 Sat Sep 28 08:38:24 EDT 2024 Wed Apr 02 07:26:03 EDT 2025 Tue Jul 01 04:11:30 EDT 2025 Thu Apr 24 22:56:00 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Amphetamine derivatives Human Sensory filter Healthy subject Rat Serotonin Toxicity Interspecific comparison Rodentia Oral administration Startle reflex Vertebrata Mammalia Acoustic stimulus Animal Double blind study Subcutaneous administration Drug of abuse Gating |
Language | English |
License | http://www.springer.com/tdm CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c346t-65c6c06285e647535bd385c834773e175e350abd99d6ea1f59efb11e6dc33ec33 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
PMID | 10367553 |
PQID | 3117833631 |
PQPubID | 47309 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_69820467 proquest_journals_3117833631 pubmed_primary_10367553 pascalfrancis_primary_1770450 crossref_primary_10_1007_s002130050960 crossref_citationtrail_10_1007_s002130050960 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 1900 |
PublicationDate | 1999-04-01 |
PublicationDateYYYYMMDD | 1999-04-01 |
PublicationDate_xml | – month: 04 year: 1999 text: 1999-04-01 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | Berlin |
PublicationPlace_xml | – name: Berlin – name: Germany – name: Heidelberg |
PublicationTitle | Psychopharmacologia |
PublicationTitleAlternate | Psychopharmacology (Berl) |
PublicationYear | 1999 |
Publisher | Springer Springer Nature B.V |
Publisher_xml | – name: Springer – name: Springer Nature B.V |
SSID | ssj0000484 ssj0068394 |
Score | 1.9007274 |
Snippet | Prepulse inhibition of acoustic startle refers to the reduction in the startle response when the startling stimulus is preceded by a weak prepulse stimulus.... Rationale: Prepulse inhibition of acoustic startle refers to the reduction in the startle response when the startling stimulus is preceded by a weak prepulse... |
SourceID | proquest pubmed pascalfrancis crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 365 |
SubjectTerms | Acoustic Stimulation Adult Affect - drug effects Analysis of Variance Animals Biological and medical sciences Blindness Dose-Response Relationship, Drug Double-Blind Method Drug addictions Drug development Drug dosages Ecstasy Habituation, Psychophysiologic - drug effects Humans Laboratory animals MDMA Medical sciences Mental disorders Middle Aged N-Methyl-3,4-methylenedioxyamphetamine - administration & dosage N-Methyl-3,4-methylenedioxyamphetamine - pharmacology Placebos Psychometrics Rats Rats, Sprague-Dawley Reflex, Startle - drug effects Schizophrenia Sensorimotor gating Serotonin Serotonin Agents - administration & dosage Serotonin Agents - pharmacology Startle response Toxicology |
Title | Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans |
URI | https://www.ncbi.nlm.nih.gov/pubmed/10367553 https://www.proquest.com/docview/3117833631 https://www.proquest.com/docview/69820467 |
Volume | 143 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1432-2072 dateEnd: 20240929 omitProxy: true ssIdentifier: ssj0000484 issn: 0033-3158 databaseCode: ABDBF dateStart: 19961001 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVLSH databaseName: SpringerLink Journals customDbUrl: mediaType: online eissn: 1432-2072 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000484 issn: 0033-3158 databaseCode: AFBBN dateStart: 19970101 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1432-2072 dateEnd: 20171231 omitProxy: true ssIdentifier: ssj0000484 issn: 0033-3158 databaseCode: 7X7 dateStart: 19970201 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1432-2072 dateEnd: 20171231 omitProxy: true ssIdentifier: ssj0000484 issn: 0033-3158 databaseCode: BENPR dateStart: 19970201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK - Czech Republic Consortium customDbUrl: eissn: 1432-2072 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000484 issn: 0033-3158 databaseCode: AGYKE dateStart: 19970101 isFulltext: true titleUrlDefault: http://link.springer.com providerName: Springer Nature – providerCode: PRVAVX databaseName: SpringerLink Journals (ICM) customDbUrl: eissn: 1432-2072 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000484 issn: 0033-3158 databaseCode: U2A dateStart: 19970101 isFulltext: true titleUrlDefault: http://www.springerlink.com/journals/ providerName: Springer Nature |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swEBdbC2MwxtZ9NOvH9DDCBjGNqg_bTyPZGsogWRgt5M3I8nkUWjutEpj_-54sJW4fugdjhIRsdCfdT9Ld7wj5IhMoY1YIlIBMI6FTESFuNpFxHhjJUEHZRshNZ-r8UvxayEU4cLPBrXKzJrYLdVEbd0Z-whmLE84VZ9-Xt5HLGuVuV0MKjedklyFUcVodL-JuJRYuCNMXFCIBT8nMXUCZTALhZhtH5ywd91Qow0cG6tVSWxyr0ie5eBqFttZo8oa8DjCSjrzc35JnUO2RF9NwUb5H-nNPSd0M6EUXYWUHtE_nHVl1847c_l62fltAg2cHrUvKByJyqaUbNEnYZf2vcSWNgoeVvsEP0K_Tn9PRN1pX1OI-GMcJJV7fUUfXUf2lVxVFxbLUuXysLfWxlg1t8wHa9-Rycnbx4zwKaRgiw4VaRUoaZdpQS1ACdzcyL3giTcJFHHNA-AFcDnVepGmhQLNSplDmjIEqDOeAzweyU9UV7BMKuRyW4Cj0i1xozXKRqtMyzk-BJYkyvEcGm7HPTOAod6kyrrMtu_JDUfVIf9t86ck5nmp49EiQXes4RkyL9YcbwWZhDtus07ge-bytxtnnrlR0BfXaZipFBIW2pkc-enV48B8c92KSf_p_1wfkpSeCcL5Ah2RndbeGI4Q5q_y41eVjsjuajMczfI_PZvM_909T-0M |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB5VRQIkVEF5pQ-6B4hAioWdfdg-IFRRqpTWpYdUys2112OEBHZaJ6L-U_xGZr123B7KrcfVrmzLM5751jvfNwBvZYC572WCLCBDRyShcAg3a0ebCozAVZg3DLnoVE3OxbeZnK3B344LY8oqu5jYBOqs1OYf-UfueX7AueLe5_mlY7pGmdPVroWGdYtjrP_Qlq36dHRA9n03Hh9-nX6ZOG1XAUdzoRaOklrphjmIShBYl2nGA6kDLnyfI2VT5NJN0iwMM4WJl8sQ89TzUGWac9TmByiF_AeCu8Jo9fszv4_8wpA-7UAR8rAS0NwQ2GTQCnw2vD2TWbmVXnFvJcQn86Qi2-S2qcbdqLfJfodPYaOFrWzf-tkzWMNiEx5G7cH8JgzPrAR2PWLTntFVjdiQnfXi2PVzuPw-b-rEkLWVJKzMGR8Jx7SyrikF0iXL69qMEnI0XCS_6QbsfXQQ7X9gZcEq2neTXcjDyitm5EGKH-xnwciRK2ZKTJYVs9zOmjX9B6sXcH4vBnoJ60VZ4GtgmEo3RyPZn6UiSbxUhGqc--kYvSBQmg9g1L37WLea6KY1x694peZ801QDGK6Wz60YyF0Ld28Zsl_t-4ShaX6nM2zcxowq7j18AHurafrazRFOUmC5rGIVEmKj3DaAV9YdbjwHp72f5Fv_v_QePJpMo5P45Oj0eBseWxEKU4e0A-uLqyXuEsRapG8av2Zwcd8f0j9gRDSk |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Nb9NAEB1VRaqQUAXlo4GW7gEikGI1zn7ZB4QqQtRSUnJopdyMvR4jpGKndSLwX-PXMeu14_ZQbj2udrW2_GZ3Zr1v3gC8kQFm2k8FISBDT8Sh8ChuNp6xDIxgqDCrM-SmZ-r4QnyZy_kG_G1zYSytst0T6406LYz9R37IfV8HnCvuH2YNLWI2nnxcXHm2gpS9aW3LaTgTOcXqNx3fyg8nY8L67Wg0-Xz-6dhrKgx4hgu19JQ0ytRZhKgEBe4ySXkgTcCF1hzJsyKXwzhJwzBVGPuZDDFLfB9VajhHY3-G0vb_QHPBLZ1Mz3XnBYRNAHUNRVGIk4PmNplNBo3YZ53DZ70sdzIsw1vO8dEiLgmnzBXYuDsCrj3h5DFsNyEsO3I29wQ2MN-BrWlzSb8D_ZmTw64G7LzL7ioHrM9mnVB29RSuvi1qzhiyhlXCiozxgfBsWeuK3CFNWfypbCsmo8Nl_IsewN5Nx9Oj96zIWUlncMKFrK24ZlYqJP_BfuaMjLpklm6yKpnL86xYXYuwfAYX9wLQc9jMixx3gWEihxla-f40EXHsJyJUo0wnI_SDQBneg0H77SPT6KPbMh2X0VrZ-SZUPeivhy-cMMhdA_dvAdmN1priaerfa4GNmv2jjDpr78HBuptWvr3OiXMsVmWkQoreyM_14IUzhxvvwekcKPnL_099AFu0hKKvJ2enr-Ch06OwlKQ92Fxer3Cfoq1l8ro2awbf73sd_QPmwDjf |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Opposite+effects+of+3%2C4-methylenedioxymethamphetamine+%28MDMA%29+on+sensorimotor+gating+in+rats+versus+healthy+humans&rft.jtitle=Psychopharmacology&rft.au=Vollenweider%2C+F.+X&rft.au=Remensberger%2C+S&rft.au=Hell%2C+D&rft.au=Geyer%2C+M.+A&rft.date=1999-04-01&rft.pub=Springer+Nature+B.V&rft.issn=0033-3158&rft.eissn=1432-2072&rft.volume=143&rft.issue=4&rft.spage=365&rft.epage=372&rft_id=info:doi/10.1007%2Fs002130050960&rft.externalDBID=HAS_PDF_LINK |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0033-3158&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0033-3158&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0033-3158&client=summon |